Several lines of evidence have demonstrated that transgenic overexpression or administration of FGF21 decrease hepatic and serum levels of lipids, reduce body weight, and alleviate the progression of NAFLD [1]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.